Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Organisation › Details

DCPrime B.V.

DCPrime is a privately owned, clinical stage biotechnology company focused on developing therapeutic, dendritic cell-based cancer vaccines. DCPrime’s technology platform is based on the DCOne® cell line, which is derived from myeloid leukemia cells and expresses a number of validated tumor antigens. This makes the platform suitable for application in patients with myeloid and other hematological cancers. In addition, DCOne® cells can be loaded with tumor associated antigens of choice, to develop cancer-specific vaccine formulations for multiple other (solid) cancer types. The company’s lead product DCP-001 is positioned as a consolidation vaccine therapy in Acute Myeloid Leukemia (AML). A Phase I/IIa study with this product has been completed and shows that DCP-001 is a safe product that induces a clear anti-tumor response in patients, and strong survival improvement in several of the studied patients. DCPrime received orphan drug designation in AML for this product from the EMA and is currently preparing a multi-center Phase II trial to demonstrate efficacy in AML patients. *

 

Period Start 2005-03-01 splitoff
Period End 2022-06-23 renamed
  Group Mendus (Group)
  Today Mendus B.V.
  Predecessor Free University of Amsterdam (Vrije Universiteit Amsterdam) (VU)
  Successor Mendus B.V.
Products Industry therapeutic vaccine
  Industry 2 DCP-001 cancer vaccine (DCPrime)
Persons Person Manting, Erik (Immunicum AB 202110 before CEO of DCPrime)
  Person 2 Kruisbeek, Ada (DCPrime BV 201710 CEO + CSO + Founder)
     
Region Region Leiden
  Country Netherlands
  Street 8 Galileiweg
Leiden Bio Science Park
  City 2333 BD Leiden
  Tel +31-71-332-2627
    Address record changed: 2022-04-28
     
Basic data Employees n. a.
     
    * Document for »About Section«: Apceth Biopharma GmbH. (10/19/17). "Press Release: DCPrime and Apceth Biopharma GmbH Announce Manufacturing Partnership". Leiden & Munich.
     
   
Record changed: 2024-02-12

Advertisement

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Mendus (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Top News How Covid Effects the Brain 650x300px




» top